Denosumab 60mg: increased risk of multiple vertebral fractures after stopping or delaying ongoing treatment
A patient’s individual factors for benefits and risks should be evaluted before initiating treatment with denosumab 60mg, particularly in those with previous vertebral fracture.
Join OnMedica and benefit from:
- Bitesize CPD and easy to digest content, free for UK-based GPs and specialist doctors
- High-quality, evidence-based content developed by expert editors and clinicians
- Articles, quizzes, videos, visual summaries and more
- Regulatory alerts and round-up of medical journals
- New content added daily, so you know you’re always up to date